Group 1 - The core viewpoint of the news is that Zhenbao Island's stock has experienced a decline, with significant trading activity and high financing levels, indicating potential investor concerns and market volatility [1][2]. Group 2 - On January 15, Zhenbao Island's stock fell by 3.07%, with a trading volume of 91.26 million yuan. The financing buy-in amount was 16.83 million yuan, while the financing repayment was 11.45 million yuan, resulting in a net financing buy of 5.39 million yuan. The total financing and securities balance reached 311 million yuan [1]. - The financing balance of Zhenbao Island is 310 million yuan, accounting for 3.48% of the circulating market value, which is above the 80th percentile level over the past year, indicating a high level of financing [1]. - On the short-selling side, Zhenbao Island had a short-selling repayment of 100 shares and a short-selling amount of 61,300 shares, with a selling amount of 581,100 yuan. The remaining short-selling volume was 97,500 shares, with a short-selling balance of 924,300 yuan, also above the 80th percentile level over the past year [1]. Group 3 - As of September 30, Zhenbao Island had 20,900 shareholders, a decrease of 2.72% from the previous period. The average circulating shares per person increased by 2.80% to 44,969 shares [2]. - For the period from January to September 2025, Zhenbao Island reported an operating income of 918 million yuan, a year-on-year decrease of 54.71%. The net profit attributable to the parent company was -373 million yuan, a year-on-year decrease of 193.81% [2]. Group 4 - Since its A-share listing, Zhenbao Island has distributed a total of 1.302 billion yuan in dividends, with 356 million yuan distributed over the past three years [3].

Group 1 - The company, Guilin Sanjin, reported that as of January 9, 2026, the total number of shareholders is 19,196 [2]

Core Viewpoint - Guangyuyuan (600771) emphasizes its commitment to quality and traditional pharmaceutical practices, ensuring the efficacy of its classic products like Gui Ling Ji and Ding Kun Dan, while maintaining strict adherence to GMP standards in production [1] Group 1: Quality Control - The company views product quality as its core lifeline, implementing a comprehensive quality control system throughout the entire process from raw material procurement to finished product release [1] - Guangyuyuan's commitment to high standards in quality management is reflected in its adherence to traditional pharmaceutical teachings, ensuring that every batch of products is stable and reliable [1] Group 2: Strategic Focus - The company will continue to focus on its "1541" strategic framework, centering on its main responsibilities and core growth objectives, with an emphasis on performance-driven management and sales breakthroughs [1] - Guangyuyuan aims to enhance operational quality while safeguarding consumer rights through its commitment to high-quality product manufacturing [1]

证券之星消息，1月15日中药板块较上一交易日下跌0.27%，*ST长药领跌。当日上证指数报收于4112.6， 下跌0.33%。深证成指报收于14306.73，上涨0.41%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603896 | 寿仙谷 | 21.98 | 6.49% | 13.51万 | | 2.94亿 | | 002424 | ST百灵 | 4.29 | 4.89% | 40.22万 | | + 1.71亿 | | 002107 | 沃华医药 | 7.38 | 2.22% | 32.02万 | | 2.37亿 | | 600422 | 昆药集团 | 13.26 | 2.16% | 1 25.18万 | | 3.34亿 | | 600566 | 济川药业 | 26.52 | 1.57% | 5.90万 | | 1.56亿 | | 603139 | 康惠股份 | 21.23 | 1.34% | 2.10万 | | 4384.67万 | | 60 ...

当前，我国糖尿病药物市场正快速扩容。"糖宁通络"保密专利的受理恰逢其时，为我国糖尿病治疗领域 注入了民族医药的创新力量。若最终获得授权，"糖宁通络"将是我国首个获得保密专利的糖尿病治疗类 中药制剂，在有效避免核心技术外泄的同时，也将进一步加快其在临床推广、市场转化等方面的步伐， 有望成为改变我国乃至全世界糖尿病治疗格局的关键药物，为亿万患者带来全新选择。 姜伟董事长表示，作为全国苗药龙头企业，公司始终致力于通过现代科技手段挖掘苗药独特价值，"糖 宁通络"的研发正是民族医药传承与创新的生动实践。此次保密专利的受理，是国家对民族医药创新成 果的认可，也是国家对重大慢性疾病防治技术自主可控的战略考量。公司将进一步加快"糖宁通络"的临 床试验与产业转化进程，力争早日惠及全球患者，为人类健康贡献更多百灵力量。（CIS） 1月14日，贵州百灵披露公告，公司基于"糖宁通络"多年研究技术形成的"一种治疗糖尿病或其并发症的 中药制剂"，申请国家保密专利已获得国家知识产权局受理。保密保护范围涵盖配方组成、生产工艺及 多个治疗范围，保密期限与《中华人民共和国国家保密法》中"机密"保密期限相同。 "糖宁通络"是贵州百灵在长期挖掘和传 ...

Core Viewpoint - The company is actively embracing "AI + smart manufacturing" to inject new vitality into pharmaceutical innovation, responding to national strategies for developing new productive forces [1] Group 1: R&D Innovations - The company has established an "AI-driven active substance discovery" and "drug screening evaluation and new drug development" technical system [1] - The KYS2301 gel utilizes an AI drug discovery platform with deep learning algorithms to analyze vast compound data, significantly shortening the preclinical research cycle [1] - Exploratory research is being conducted in AI-enabled traditional Chinese medicine (TCM) development, focusing on discovering effective substances, identifying potential indications, and optimizing compound analysis [1] Group 2: Manufacturing Advancements - The company has pioneered a smart manufacturing technology system centered on effective ingredient groups, establishing the first intelligent production factory for TCM in China [1] - The self-developed Pharmaceutical Knowledge System (PKS) overcomes the bottleneck of big data application in the pharmaceutical industry, transitioning TCM production from traditional experience-based methods to precise and intelligent processes [1] Group 3: Future Directions - The company plans to continue deepening the application of AI technology across the entire chain of R&D, production, and quality control, aiming for innovative outcomes that benefit investors [1]

格隆汇1月14日丨ST百灵(002424.SZ)公布，近日收到国家知识产权局出具的《专利申请受理通知书》， 发明创造名称：一种治疗糖尿病或其并发症的中药制剂。本次国家知识产权局受理的"一种治疗糖尿病 或其并发症的中药制剂"国家保密专利申请，是基于公司糖宁通络项目多年研究所形成的专利技术。保 密保护范围涵盖配方组成、生产工艺及多个治疗范围，保密期限与《中华人民共和国国家保密法》 中"机密"保密期限相同。此次保密专利的受理，将为公司糖宁通络提供全方位且更严密的核心知识产权 保护。若最终获得专利授权，公司糖宁通络项目将在有效避免核心技术外泄的同时，进一步加快其在临 床推广、市场转化等方面的步伐，增强公司核心竞争力。 ...

Core Viewpoint - ST Bailin (002424.SZ) has received a patent application acceptance notice from the National Intellectual Property Administration for a traditional Chinese medicine formulation aimed at treating diabetes and its complications, which will enhance the company's core intellectual property protection [1] Group 1: Patent Application Details - The accepted patent application is for a "traditional Chinese medicine formulation for treating diabetes or its complications," based on years of research from the company's Tang Ning Tong Luo project [1] - The confidentiality protection scope includes formula composition, production processes, and multiple treatment areas, with a confidentiality period aligned with the "secret" confidentiality period under the National Confidentiality Law of the People's Republic of China [1] Group 2: Implications for the Company - The acceptance of this confidential patent will provide comprehensive and tighter core intellectual property protection for the Tang Ning Tong Luo project [1] - If the patent is ultimately granted, it will help the company avoid core technology leakage and accelerate clinical promotion and market transformation, thereby enhancing the company's core competitiveness [1]

贵州百灵公告称，公司近日收到国家知识产权局出具的《专利申请受理通知书》。受理的专利申请号为 202610042695.2，发明创造名称是"一种治疗糖尿病或其并发症的中药制剂"。该申请基于公司糖宁通络 项目多年研究形成的专利技术，若获授权，将为项目提供更严密知识产权保护。不过，此次申请处于受 理环节，存在无法通过审查并获授权的风险，且目前不会对公司经营产生重大影响。 ...

Core Viewpoint - The announcement from Zhenbao Island indicates that the controlling shareholder, Chuangda Group, will exchange 8.842536 million shares of convertible bonds, reducing its shareholding from 57.92% to 56.98% between October 24, 2025, and January 12, 2026. This change is due to the conversion of convertible bonds and does not affect the controlling shareholder or actual controller of the company, nor does it trigger a mandatory bid or require additional disclosure [1]. Group 1 - The exchange of convertible bonds will lead to a decrease in the controlling shareholder's stake from 57.92% to 56.98% [1] - The change in shareholding is attributed to the conversion of convertible bonds, which is currently in the conversion period [1] - The company will disclose any subsequent changes in equity as required by regulations [1]